HealthCor Management L.P. decreased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 41.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 202,180 shares of the pharmaceutical company’s stock after selling 143,370 shares during the period. Vertex Pharmaceuticals accounts for about 1.3% of HealthCor Management L.P.’s holdings, making the stock its 28th largest holding. HealthCor Management L.P. owned about 0.08% of Vertex Pharmaceuticals worth $38,968,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Stratos Wealth Partners LTD. purchased a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth approximately $123,000. Sun Life Financial INC grew its holdings in shares of Vertex Pharmaceuticals by 266.1% during the 2nd quarter. Sun Life Financial INC now owns 692 shares of the pharmaceutical company’s stock worth $118,000 after acquiring an additional 503 shares during the period. Flagship Harbor Advisors LLC purchased a new position in shares of Vertex Pharmaceuticals during the 2nd quarter worth approximately $125,000. TRUE Private Wealth Advisors purchased a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth approximately $169,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth approximately $170,000. 93.79% of the stock is owned by institutional investors and hedge funds.
Vertex Pharmaceuticals stock opened at $170.06 on Friday. The company has a current ratio of 3.71, a quick ratio of 3.59 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $44.32 billion, a P/E ratio of 212.58, a P/E/G ratio of 1.72 and a beta of 1.65. Vertex Pharmaceuticals Incorporated has a twelve month low of $142.05 and a twelve month high of $194.92.
VRTX has been the topic of a number of research analyst reports. Zacks Investment Research downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, September 11th. Raymond James initiated coverage on Vertex Pharmaceuticals in a report on Tuesday, October 2nd. They set a “buy” rating on the stock. HC Wainwright upgraded Vertex Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $220.00 target price on the stock in a report on Friday, October 26th. Oppenheimer set a $200.00 target price on Vertex Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, November 27th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $217.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, November 27th. Three equities research analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $202.38.
In related news, CFO Thomas Graney sold 1,076 shares of the company’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $193.24, for a total value of $207,926.24. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Paul M. Silva sold 809 shares of the company’s stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $186.52, for a total value of $150,894.68. Following the completion of the sale, the senior vice president now owns 16,896 shares in the company, valued at approximately $3,151,441.92. The disclosure for this sale can be found here. Insiders sold a total of 28,346 shares of company stock worth $5,264,953 in the last 90 days. 0.75% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This article was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.com-unik.info/2018/12/16/vertex-pharmaceuticals-incorporated-vrtx-holdings-reduced-by-healthcor-management-l-p.html.
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.
Featured Story: Put Option
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.